Disclaimer

The information contained in these pages is not meant to be taken as an endorsement of any medical approach, procedure, or treatment of any kind. If you have symptoms, seek immediate professional medical attention. The topics here are presented solely as potential options to be discussed with your medical professional.
Oncovite PDF Print E-mail

Dr. DL Lamm [http://www.bcgoncology.com] has been a pioneer in the field of immunotherapy for bladder cancer since the early ‘80’s. After 28 years of academic practice, Dr. Lamm has opened a private practice limited to genito-urinary oncology:
Bladder Cancer, Genitourinary Oncology; BCG Oncology, P.C.
16620 N. 40th St. Suite E, Phoenix AZ 85032
tel: 602 493 6626.

Also on WebCafe:
Dr. Lamm's BCG protocol
Interview with Dr. Lamm, 2005

Improves results for those undergoing BCG treatments.

Dr. Donald Lamm is one of the world’s leading authorities in the field of urology/oncology, has been conducting studies using a high anti oxidant vitamin formula designed especially for bladder cancer patients undergoing BCG treatments. In a double-blind study, high doses of vitamins A, B6, C, and E plus zinc reduced the long-term recurrence of bladder cancer by 40% in patients receiving intravesical BCG immunotherapy. In view of his findings, Dr. Lamm has worked together with Mission Pharmacal to develope Oncovite, which is now available for the public.

New trials are being planned using a new and hopefully improved combination of vitamins. The modifications that have been made are based on evidence that vitamin D and folic acid are also beneficial in cancer, particularly prostate cancer. There is some evidence that D may be useful in bladder cancer as well. The modified preparation is the one that is now commercially available from Mission Pharmacal. Dr. Lamm’s research group hopes to start new studies using the new preparation in 1999 if FDA gives their OK. Their 1994 study was updated a few years ago it was found at 6 yrs follow up that only one additional patient on Oncovite had a new tumor. That amounted to a 37% reduction in recurrence compaired to RDA vitamins.

The dose of Oncovite is two tabs twice a day, unless one weighs less than 100 lb, in which case three tabs a day are advised. Those with liver disease should take reduced dose (one tablet or less). The A has been reduced in the new preparation as has the Zinc. After several years, it is probably safe to reduce the intake, eg to 3/day for years 4-8 and 2/day thereafter.

Bladder cancer warriors are very grateful that a leading expert is focusing on an issue about which patients are eager for answers; use of vitamins to prevent or delay recurrence of cancer. Hopefully the FDA will give their approval to Dr. Lamm and his team to further investigate the use of Oncovite.

Oncovite ingredients
Vitamin A: 9,000 IU
Vitamin C: 500 mg
Vitamin D3: 400 IU
Vitamin E: 100 IU
Vitamin B1: 0.37 mg
Vitamin B2: 0.5 mg
Vitamin B3: 5mg
Vitamin B6: 25 mg
Folate: 0.4 mg
Vitamin B12: 1.6 mg
Vitamin B5: 2.5 mg
Zinc: 7.5 mg

Oncovite can be ordered by your pharmacist through the manufacturer, Mission Pharmacal (1-800-531-3333). You can buy Oncovite online at http://www.drugstore.com for $19.99/100 capsule bottle.

International patients may purchase Oncovite directly from Mission Pharmacal, since they do not have distributors for this product worldwide. Contact: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it for prices and arrangements for payment.

For further reading: Diana Dyer's page: http://www.cancerrd.com/FAQs/FAQ50.htm

Reference

1. Megadose vitamins in bladder cancer: a double-blind clinical trial.
Lamm DL; Riggs DR; Shriver JS; vanGilder PF; Rach JF; DeHaven JI
Department of Urology, West Virginia University School of Medicine, Morgantown.
J Urol 1994 Jan;151(1):21-6 PMID: 8254816 UI: 94076504

Last Updated ( Friday, 14 November 2008 )
 
Bladder Cancer WebCafé